Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy

Atomoxetine is a non-stimulant medication used to treat attention-deficit/hyperactivity disorder. CYP2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Brown, Jacob T., Bishop, Jeffrey R., Sangkuhl, Katrin, Nurmi, Erika L., Mueller, Daniel J., Dinh, Jean C., Gaedigk, Andrea, Klein, Teri E., Caudle, Kelly E., McCracken, James T., de Leon, Jose, Leeder, J. Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612570/
https://ncbi.nlm.nih.gov/pubmed/30801677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1409
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados